TD Cowen Maintains Buy on Tandem Diabetes Care, Raises Price Target to $28
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $25 to $28.
TD Cowen analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $25 to $28.